JPRN-jRCT1030200192进行中（未招募）未知
Translational research for a Phase I study of tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
Mitsunaga Shuichi0 个研究点目标入组 10 人开始时间: 2020年11月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Partipants for a Phase I study of tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
- •2. Tumor tissue from the patient was available
- •3. Written informed consent for participation in the study is obtained at the discretion of the patient.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Phase 2 trial of Translational approach to first line cHemoimmunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensive-Stage Small-Cell Lung CanceR (THOR trial)CTIS2024-514666-39-00Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.60
进行中（未招募）
1 期
Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplificatioung CancerMedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2CTIS2024-512003-39-00Merck Healthcare KGaA126
进行中（未招募）
1 期
Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplificatioEUCTR2015-005696-24-BEMerck KGaA200
进行中（未招募）
1 期
Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplificatioAdvanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterationsEUCTR2015-005696-24-DEMerck KGaA200
进行中（未招募）
1 期
Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplificatioAdvanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterationsEUCTR2015-005696-24-ATMerck KGaA200